WaveMan
WaveMan · Company
BFNH · Bioforce Nanosciences Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BFNH Bioforce Nanosciences (BFNH) Insider Trading, Ownership & Congress Trades

Medical Devices · Laboratory analytical instruments · CIK 0001310488
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about BFNH

Activist stakes (13D), 180 days
1 filing
Largest: 79.6% of the class

Bioforce Nanosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BIOFORCE NANOSCIENCES HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Ferguson Merle
Director
SELL
2026-09-02 SECtraded 2026-04-22
26,700,000
$400.5K
+36.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
Insider activity: Director Ferguson Merle sold about $400.5K of BFNH on Apr 22, 2026, the largest insider sale at the company on our record.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+9.0% year over year
below 51% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 94% of Medical Devices
The situation: each line is one rule over one dataset
Nexus Capital Investments, Inc. disclosed a 5%+ stake (79.6%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BFNH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+875.6%12M
-78%+322%+721%+1121%2025-102025-122026-022026-042026-062026-082026-10 2026-04-22 · Ferguson Merle sold $400.5K2026-09-04 · Nexus Capital Investments, Inc. filed a 5%+ stake (79.6%)
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BFNH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BFNH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Nexus Capital Investments, Inc.
Activist 13D · 2026-09-04
79.6%

BFNH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BFNH financials

Revenue growth
+9.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$17.8K
four quarters, 2019-01-01 to 2019-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-10.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-8.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
800.00x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$1.3M-$490.4K-$472.0K-$485.5K
EPS (diluted)-0.04-0.02-0.02-0.02
Operating cash flow-$65.2K-$61.2K-$46.7K-$68.4K
Cash$786$862$638$734
SEC XBRL, fiscal years, as known on 2026-10-27

BFNH Stock Sonar score 3/7 axes

Find similar shapesCompare

BFNH ranks highest on risk and compliance (96th percentile) and profitability (57th), and lowest on growth (49th), among Medical Devices peers.

Profitability
57
Inputs
  • Return on equity-10.2% · 57 pct, sector of 183
  • Return on assets-8.2% · 58 pct, sector of 214
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Growth
49
Inputs
  • Revenue growth, YoY+9.0% · 49 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
96
Inputs
  • Short interest, % of float+0.0% · 93 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+0.0% · 100 pct, sector of 198
4 not measured: Financial health, Insider conviction, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BFNH filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 79.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies